In this article, we are going to take a look at where Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stands against other stocks Insiders are selling in March. Wall Street experienced a ...

MICHELLE RENEE GRIFFIN, a director at $ADPT, sold 36,291 shares of the company on 03-13-2025 for an estimated $260,932. We received data on the trade from a recent ...

ROBERT HERSHBERG, a director at $ADPT, sold 53,000 shares of the company on 03-12-2025 for an estimated $402,270. We received data on the trade from a recent SEC ...

The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies (NASDAQ:ADPT – Free Report) from a neutral rating to a buy rating in a research report released on Friday, Marketbeat.com reports.

Shares of Adaptive Biotechnologies (NASDAQ:ADPT) climbed in the morning hours on Friday after Goldman Sachs upgraded the stock to Buy from Neutral, arguing that the cancer test maker operates in ...

Adaptive Biotechnologies (ADPT – Research Report) received a Buy rating and price target from Goldman Sachs analyst Matthew Sykes today. The company’s shares closed yesterday at $7.75.

In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on Adaptive Biotechnologies (ADPT – Research Report), with a price target of $10.00. The company’s shares closed ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system ...